Japan’s shortage of transplant organs

Japan’s shortage of transplant organs is the scarcity against which the book sets Tadamasa Goto’s liver transplant at UCLA. Donors were few and operations rare, leaving many people in Japan who needed an organ to go abroad or die waiting. Goto’s successful treatment in the United States therefore raises questions about who can reach scarce medical care, how cross-border arrangements are scrutinized, and what remains unknown about the money involved.

Scarcity and Goto’s medical circumstances

In January or February 2001, doctors at Showa University told Goto that he would die without a liver transplant soon. He had hepatitis C and a heart condition, and was considered a very unlikely candidate for a transplant in Japan. The urgency of his condition thus met a system the book describes as having few donors and rare transplant operations, where many Japanese patients in need had to seek treatment abroad or wait without receiving it.

The account uses this mismatch to establish the significance of Goto’s eventual operation, not to claim that any particular patient lost a place to him. His case instead makes the limits and consequences of scarcity visible: access to a transplant depended not only on medical need, but also on the ability to cross borders and secure treatment elsewhere.

The route to treatment in the United States

In April 2001, Goto approached the FBI through Hoshi Hitoshi, a former political fixer with connections to the Liberal Democratic Party. The FBI wanted information about organized crime figures in Japan, which the National Police Agency had declined to share on privacy grounds. Goto offered a comprehensive list of Yamaguchi-gumi members, associated front companies and financial institutions, as well as information about North Korean activities.

In exchange, Goto sought a U.S. visa so he could receive a liver transplant at UCLA. The book distinguishes the visa arrangement from the medical treatment: the FBI pressured U.S. Immigration and Customs Enforcement to grant the visa, while UCLA carried out the transplant. The surgery took place on July 5, 2001. According to the account, Goto supplied only a fraction of the information he had promised, returned to Japan after the operation, and did not speak to the FBI again.

Oversight, payment, and unresolved questions

The book places Goto’s case alongside evidence that three other Japanese patients with yakuza ties also received liver transplants at UCLA. It stresses that neither UCLA nor Dr. Busuttil was proven to have known of the patients’ organized-crime connections at the time of the operations. UCLA and the doctor said they did not make moral judgments about patients and treated them according to medical needs; the account also notes that they did not explicitly address what they knew about the four patients’ ties or when they knew it.

An investigation by the U.S. Centers for Medicare and Medicaid Services and UCLA found no evidence of improper conduct by the medical center or its staff. That finding did not settle the ethical questions raised by treating foreign patients with criminal records amid organ scarcity, including whether nationality, resources, or access to exceptional arrangements affected opportunity. The book presents these as questions about fairness and transparency, not as proof that a particular American patient was displaced.

It also raises a separate concern about payment. Federal law-enforcement sources told the narrator that money paid to UCLA by at least one of the four patients with yakuza ties might have come from illegal activity in Japan, which could implicate the case in international money laundering. The account says none of the men had been investigated for money laundering and that any such inquiry would require Japanese authorities’ cooperation. Whether UCLA knew about the patients’ yakuza ties or the possible origins of their payments remains unresolved.

Significance

The scarcity of organs gives the episode its wider stakes, but it does not by itself establish wrongdoing by doctors or prove that access was allocated unfairly. The account keeps distinct the clinical decision to treat a patient, the transplant system’s distribution of a limited resource, and the scrutiny of money crossing borders. By holding those questions together while preserving the limits of what was established, it presents Goto’s transplant as both a rescue from imminent medical danger and a test of the transparency and accountability surrounding scarce care.